Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston's longer DES (drug-eluting stent) shelf life:

This article was originally published in Clinica

Executive Summary

The US FDA has given Boston Scientific the all-clear to extend the shelf life of its Taxus Express2 paclitaxel-eluting coronary stent from 12 months to 18 months. Boston noted that its extended shelf life is three times longer in the US than that for rival US drug-eluting stent (DES) Cypher, made by Johnson & Johnson. An extended shelf life may help facilitate inventory management for hospitals concerned with product expiration of DESs. Taxus' shelf life outside the US remains unchanged at 18 months.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel